IP Library Granted Patent US 7,943,612
Granted Patent B2
US 7,943,612 · App. 12/282,244 · Granted May 17, 2011

Compounds that modulate PPAR activity, their preparation and use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,943,612
App. No.
12/282,244
Granted
May 17, 2011
Kind
B2
Abstract

Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are activators of PPARδ and should be useful for treating conditions mediated by the same.

Claims (58)

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:

wherein X 1 is aryl, heteroaryl or heterocyclyl each of which is optionally substituted with one or more substituents, where said substituents independently are:

halogen, perhalomethyl, hydroxy, cyano, amino or carboxy; or

C 1-6 -alkyl, C 3-6 -cycloalkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, C 1 - 6 -alkoxy, C 3-6 -cycloalkoxy, aryloxy, aralkoxy, heteroaralkoxy, C 1-6 -alkylthio, arylthio, C 3-6 -cycloalkylthio, C 1-6 -alkylcarbonyl, arylcarbonyl, C 1-6 -alkylsulfonyl, arylsulfonyl, C 1-6 -alkyl-amido, arylamido, C 1-6 -alkylaminocarbonyl, C 1-6 -alkylamino, C 1-6 -dialkylamino or C 3-6 -cycloalkylamino, each of which is optionally substituted independently with one or more hydroxyl groups or halogens; or

X 1 is aralkyl, heteroaralkyl or heterocyclyl-C 1-6 -alkyl, each of which is optionally substituted with one or more substituents, where said substituents independently are:

halogen, perhalomethyl, hydroxy, cyano, amino or carboxy; or

C 1-6 -alkyl, C 3-6 -cycloalkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, C 1-6 -alkoxy, C 3-6 -cycloalkoxy, aryloxy, aralkoxy, heteroaralkoxy, C 1-6 -alkylthio, arylthio, C 3-6 cycloalkylthio, C 1-6 -alkylcarbonyl, arylcarbonyl, C 1-6 -alkylsulfonyl, arylsulfonyl, C 1-6 -alkyl-amido, arylamido, C 1-6 -alkylaminocarbonyl, C 1-6 -alkylamino, C 1-6 -dialkylamino or C 3-6 -cycloalkylamino each of which is optionally substituted independently with one or more hydroxyl groups or halogens;

X 2 is hydrogen or halogen; or

X 2 is aryl-C 2-6 -alkynyl, heteroaryl-C 2-6 -alkynyl, heterocyclyl-C 2-6 -alkynyl, aryl-C 2-6 -alkenyl, heteroaryl-C 2-6 -alkenyl, heterocyclyl-C 2-6 -alkenyl, aryl or heteroaryl each of which is optionally substituted with one or more substiuents, where said substituents independently are:

halogen, perhalomethyl, hydroxy, cyano, amino or carboxy; or

C 1-6 -alkyl, C 3-6 -cycloalkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl-C 1-6 -alkyl, C 1-6 -alkoxy, C 3-6 -cycloalkoxy, aryloxy, aralkoxy, heteroaralkoxy, C 1-6 -alkylthio, arylthio, C 3-6 -cycloalkylthio, C 1-6 -alkylcarbonyl, arylcarbonyl, C 1-6 -alkylsulfonyl, arylsulfonyl, C 1-6 -alkylamido, arylamido, C 1-6 -alkylaminocarbonyl, C 1-6 -alkylamino, C 1-6 -di-alkylamino or C 3-6 -cycloalkylamino, each of which is optionally substituted independently with one or more hydroxyl groups or halogens;

Ar is arylene which is optionally substituted with one or more substituents, where said substituents independently are:

halogen, hydroxy or cyano; or

C 1-6 -alkyl, C 3-6 -cycloalkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, C 1-6 -alkoxy, C 3-6 -cycloalkoxy, aryloxy, aralkoxy, heteroaralkoxy, C 1-6 -alkylthio, arylthio or C 3-6 -cycloalkylthio, each of which is optionally substituted with one or more halogens; or

two of the substituents when placed in adjacent positions together with the atoms to which they are attached may form a five to eight member ring;

Y 1 is O or S;

Y 2 is O or S;

Z is —(CH 2 ) n — wherein n is 1, 2 or 3; and

R is hydrogen;

or a hydrate of any of the foregoing.

2. The compound according to claim 1 , wherein X 1 is aryl, heteroaryl or heterocyclyl each of which is optionally substituted with one or more substituents, where said substituents independently are:

halogen, perhalomethyl or hydroxy; or

C 1-6 -alkyl, C 3-6 -cycloalkyl, aryl, aralkyl, C 1-6 -alkoxy, C 1-6 -alkylsulfonyl or arylsulfonyl, each of which is optionally substituted with one or more halogens.

3. The compound according claim 1 wherein X 1 is aralkyl, heteroaralkyl or heterocyclyl-C 1-6 -alkyl each of which is optionally substituted with one or more substituents, where said substituents independently are:

halogen, perhalomethyl or hydroxy; or

C 1-6 -alkyl, C 3-6 -cycloalkyl, aryl, aralkyl, C 1-6 -alkoxy, C 1-6 -alkylsulfonyl or arylsulfonyl, each of which is optionally substituted with one or more halogens.

4. The compound according to claim 1 wherein X 2 is halogen.

5. The compound according to claim 1 wherein X 2 is aryl-C 2-6 -alkynyl, heteroaryl-C 2-6 -alkynyl, heterocyclyl-C 2-6 -alkynyl, aryl-C 2-6 -alkenyl, heteroaryl-C 2-6 -alkenyl, heterocyclyl-C 2-6 -alkenyl, aryl or heteroaryl each of which is optionally substituted with one or more substituents, where said substituents independently are:

halogen, perhalomethyl or hydroxy; or

C 1-6 -alkyl, C 3-6 -cycloalkyl, aryl, aralkyl, C 1-6 -alkoxy, C 1-6 -alkylsulfonyl or arylsulfonyl, each of which is optionally substituted with one or more halogens.

6. The compound according to claim 5 wherein X 2 is heterocyclyl-C 2-6 -alkynyl, which is optionally substituted with one or more substituents, where said substituents independently are:

halogen, perhalomethyl or hydroxy; or

C 1-6 -alkyl, C 3-6 -cycloalkyl, aryl, aralkyl, C 1-6 -alkoxy, C 1-6 -alkylsulfonyl or arylsulfonyl, each of which is optionally substituted with one or more halogens.

7. The compound according to claim 1 wherein Ar is phenylene which is optionally substituted with one or more substituents, where said substituents independently are:

halogen; or

C 1-6 -alkyl, C 1-6 -alkoxy, aryloxy or aralkoxy each of which is optionally substituted with one or more halogens; or

two of the substituents when placed in adjacent positions together with the atoms to which they are attached form a five-membered carbon cycle.

8. The compound according claim 1 wherein X 1 is heterocyclyl-C 1-6 -alkyl, which is optionally substituted with one or more substituents, where said substituents independently are:

halogen, perhalomethyl or hydroxy; or

C 1-6 -alkyl, C 3-6 -cycloalkyl, aryl, aralkyl, C 1-6 -alkoxy, C 1-6 -alkylsulfonyl or arylsulfonyl, each of which is optionally substituted with one or more halogens.

9. The compound according to claim 8 wherein Y 1 is O.

10. The compound according to claim 9 wherein Y 2 is O.

11. The compound according to claim 10 wherein n is 1.

12. A compound, which is a compound selected from the group consisting of:

{4-[3-(3-Bromo-5-phenylethynyl-phenyl)-prop-2-ynyloxy]-phenoxy}-acetic acid;

{4-[3-(3,5-Bis-phenylethynyl-phenyl)-prop-2-ynyloxy]-phenoxy}-acetic acid;

(4-{3-[3-Bromo-5-(3-piperidin-1-yl-prop-1-ynyl)-phenyl]-prop-2-ynyloxy}-2-methyl-phenoxy)-acetic acid;

(2-Methyl-4-{3-[3-(3-piperidin-1-yl-prop-1-ynyl)-5-(4-trifluoromethyl-phenylethynyl)-phenyl]-prop -2-ynyloxy}-phenoxy)-acetic acid;

(4-{3-[3,5-Bis-(3-piperidin-1-yl-prop-1-ynyl)-phenyl]-prop-2-ynyloxy}-2-methyl-phenoxy)-acetic acid;

(4-{3-[3-Bromo-5-(3-morpholin-4-yl-prop-1-ynyl)-phenyl]-prop-2-ynyloxy}-2-methyl-phenoxy)-acetic acid;

(2-Methyl-4-{3-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-(4-trifluoromethyl-phenylethynyl)-phenyl]-prop -2-ynyloxy}-phenoxy)-acetic acid;

(2-Methyl-4-{3-[3-(3-morpholin-4-yl-prop-1-ynyl)-5-phenylethynyl-phenyl]-prop-2-ynyloxy}-phenoxy)-acetic acid;

(4-{3-[3-(4-Chloro-phenylethynyl)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenyl]-prop-2-ynyloxy}-2-methyl-phenoxy)-acetic acid;

(4-{3-[3-(4-Methanesulfonyl-phenylethynyl)-5-(3-morpholin-4-yl-prop-1-ynyl)-phenyl]-prop-2-ynyloxy }-2-methyl-phenoxy)-acetic acid; and

(4-{3-[3-Bromo-5-(4-trifluoromethyl-phenylethynyl)-phenyl]-prop-2-ynyloxy}-2-methyl-phenoxy)-acetic acid;

or a pharmaceutically acceptable salt thereof, or a hydrate of any of the foregoing.

13. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or excipient.

14. A pharmaceutical composition comprising a compound according to claim 12 and a pharmaceutically acceptable carrier or excipient.

Assignments (3)
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS FOR REEL/FRAME 030982/0793 Recorded Apr 7, 2014
From: M&F TTP HOLDINGS LLC
To: HIGH POINT PHARMACEUTICALS, LLC
Reel/Frame 032621/0867 →
SECURITY AGREEMENT Recorded Aug 9, 2013
From: HIGH POINT PHARMACEUTICALS, LLC
To: M&F TTP HOLDINGS LLC C/O MACANDREWS & FORBES HOLDINGS INC.
Reel/Frame 030982/0793 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2008
From: SAUERBERG, PER
To: HIGH POINT PHARMACEUTICALS, LLC
Reel/Frame 021591/0534 →